Trust Signals
Key Takeaways
- Retatrutide is a once-weekly subcutaneous injection. The Phase 2 trial (Jastreboff et al., NEJM 2023) used dose steps from 0.5 mg up to 12 mg per week.
- The 12 mg cohort achieved a mean body weight reduction of approximately 24.2% at 48 weeks in that trial (n=338 active arm participants across dose groups).
- Retatrutide is a triple agonist: GLP-1, GIP, and glucagon receptors. This mechanism differs from semaglutide (GLP-1 only) and tirzepatide (GLP-1 plus GIP), and changes the tolerability and escalation profile.
- Lyophilized powder reconstituted with bacteriostatic water must be stored refrigerated and used within a defined window. Peptide degradation is invisible to the naked eye, which creates a serious under-recognized risk.
- Retatrutide is not FDA-approved as of mid-2026. Using it outside a clinical trial is not equivalent to using an approved, pharmaceutical-grade medication.
Direct Answer: How Do You Take Retatrutide Peptide?
Retatrutide is taken as a once-weekly subcutaneous injection into the abdomen, thigh, or upper arm. You start at a low dose (typically 0.5 mg to 1 mg per week), hold for 4 weeks, then escalate stepwise toward a maintenance dose. Dose, volume, and injection technique depend on the concentration of your reconstituted solution.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of Contents
- What is retatrutide and how does it work?
- Evidence ledger: what the data actually shows
- What dose and escalation schedule is used?
- How do you inject retatrutide correctly?
- How do you reconstitute retatrutide from powder?
- How should retatrutide be stored?
- What most pages get wrong about taking retatrutide
- Retatrutide vs. semaglutide vs. tirzepatide: honest comparison
- How to read a retatrutide COA and label
- What side effects should you expect and when?
- FAQ
- Sources
- Footer Disclaimers
What Is Retatrutide and How Does It Work?
Retatrutide (LY3437943) is a single synthetic peptide that simultaneously activates three receptors: the glucagon-like peptide-1 receptor (GLP-1R), the glucose-dependent insulinotropic polypeptide receptor (GIPR), and the glucagon receptor (GCGR). This triple agonism is its defining pharmacological feature.
GLP-1R activation reduces appetite and slows gastric emptying. GIPR activation complements appetite suppression and may reduce nausea at higher GLP-1 exposures, based on mechanistic data from tirzepatide studies. GCGR activation increases energy expenditure and hepatic fat oxidation, which is absent from both semaglutide and tirzepatide. The GCGR component is the theoretical basis for retatrutide's higher weight loss ceiling, but it also contributes to a more complex tolerability profile.
The half-life of retatrutide in the Phase 2 trial data supports once-weekly dosing, consistent with other fatty-acid conjugated GLP-1 class peptides, though the exact elimination half-life in humans is not precisely disclosed in the published trial report.
Evidence Ledger: What the Data Actually Shows
| Claim | Best evidence type | Source | Effect direction | Confidence |
|---|---|---|---|---|
| Once-weekly SC injection is effective for weight loss | Phase 2 human RCT, double-blind, placebo-controlled | Jastreboff et al., NEJM 2023 | Strong positive, dose-dependent | Moderate (Phase 2, single trial) |
| 12 mg dose group: ~24.2% mean body weight reduction at 48 weeks | Phase 2 RCT | Jastreboff et al., NEJM 2023 | Positive, largest reported for a weekly injectable at this stage | Moderate |
| GCGR agonism increases energy expenditure beyond GLP-1/GIP alone | Preclinical animal data, mechanistic inference | Multiple preclinical studies; not confirmed in human sub-study | Positive (directional) | Low |
| GI adverse events (nausea, vomiting, diarrhea) are most common during escalation | Phase 2 RCT | Jastreboff et al., NEJM 2023 | Adverse, dose-dependent, mostly transient | Moderate |
| Slow dose escalation reduces GI side effect burden | Clinical inference from GLP-1 class data; no retatrutide-specific RCT on escalation speed | Class-level evidence from semaglutide/tirzepatide trials | Supportive | Low to moderate |
| Long-term cardiovascular outcomes benefit | No data yet (Phase 3 ongoing as of mid-2026) | N/A | Unknown | Very low |
| Research-grade retatrutide purity equals pharmaceutical grade | No comparative study; COA-dependent | N/A | Cannot assume equivalence | Very low |
What Dose and Escalation Schedule Is Used?
The Jastreboff 2023 Phase 2 trial tested four active dose groups: 1 mg, 4 mg, 8 mg, and 12 mg weekly, each preceded by a gradual escalation period from 0.5 mg. The published supplementary appendix describes escalation steps at approximately 4-week intervals. No single universally adopted protocol exists outside that trial framework.
| Week | Suggested dose (research context) | Rationale |
|---|---|---|
| 1 to 4 | 0.5 mg once weekly | Minimize GI burden at initiation |
| 5 to 8 | 1 mg once weekly | Assess tolerability before escalating |
| 9 to 12 | 2 mg once weekly | Step toward therapeutic range |
| 13 to 16 | 4 mg once weekly | Corresponds to lowest active trial arm |
| 17 to 24+ | 4 to 12 mg based on tolerance | Individualized; higher doses drove greater weight loss but more adverse events |
How Do You Inject Retatrutide Correctly?
Use a 29 to 32 gauge, 4 to 8 mm insulin or pen needle. Shorter 4 mm needles reduce risk of inadvertent intramuscular injection, particularly in lean individuals where subcutaneous tissue depth is limited.
Approved injection sites: the abdomen (at least 5 cm from the navel), the outer thigh, and the outer upper arm. Rotate sites each week. Injecting repeatedly into the same location causes lipohypertrophy, a fibrous change in subcutaneous tissue that unpredictably slows and flattens absorption, documented extensively in insulin literature and applicable to all subcutaneous peptides.
Technique: pinch a skin fold if you are lean, insert at 45 to 90 degrees depending on tissue depth, inject slowly, hold for 5 to 10 seconds, then withdraw. Do not rub the site. Rubbing can accelerate local absorption and increase the rate of side effects immediately post-injection.
How Do You Reconstitute Retatrutide From Powder?
Most research-grade retatrutide is supplied as lyophilized (freeze-dried) powder in a sealed vial, labeled with the total milligrams present. You add bacteriostatic water (not sterile water, not saline, unless you will use the entire vial in one session) to reach a target concentration.
Concentration math example: if a vial contains 10 mg and you add 2 mL of bacteriostatic water, you have a 5 mg/mL solution. A 0.5 mg dose requires 0.1 mL (10 units on an insulin syringe). A 2 mg dose requires 0.4 mL (40 units). Always confirm your math before drawing.
Add water slowly along the inside glass wall of the vial. Do not aim the stream directly at the powder cake, as this can cause foaming and peptide degradation at the air-liquid interface. Gently swirl for 60 to 90 seconds. Never shake. Shaking introduces air bubbles and mechanical shear that can disrupt peptide conformation. The solution should be clear and colorless. Any cloudiness, particulate matter, or color change means the peptide has likely degraded or was contaminated. Do not use it.
How Should Retatrutide Be Stored?
Unreconstituted lyophilized retatrutide: refrigerate at 2 to 8 degrees Celsius. Protect from light. Most suppliers recommend using within 12 to 24 months of manufacture when stored correctly, though this is supplier-specific, not independently validated for non-pharmaceutical grade material.
Reconstituted solution: refrigerate at 2 to 8 degrees Celsius. Bacteriostatic water (containing benzyl alcohol as a preservative) extends the usable window compared to sterile water. The commonly cited 28-day post-reconstitution window for research peptides is a conservative practical guideline, not a retatrutide-specific validated stability endpoint.
Do not freeze reconstituted peptide. Freezing and thawing causes ice crystal formation that mechanically disrupts peptide structure. Short-term transport at room temperature (up to several hours) is generally acceptable for lyophilized material but should be minimized for reconstituted solution.
What Most Pages Get Wrong About Taking Retatrutide
The single biggest omission on commodity retatrutide pages is the bioavailability and purity gap between research-grade material and a pharmaceutical-grade drug product.
Retatrutide is not FDA-approved. Research-grade vials from peptide suppliers are not manufactured under pharmaceutical Current Good Manufacturing Practice (cGMP) regulations. The COA on a peptide vial shows purity by HPLC, but that test does not screen for: bacterial endotoxins (which cause fever and inflammation at microgram doses), residual solvents, microbial contamination, or the presence of the correct stereoisomers versus undesired enantiomers. A 98% HPLC purity reading means 2% of what is in the vial is something else, and that something else is uncharacterized.
The second omission is that peptide degradation is invisible. A vial of degraded retatrutide looks identical to a vial of active retatrutide. There is no color change, no precipitation, no odor cue. The only signal is loss of efficacy or unexpected side effects, both of which can be attributed to dose or individual response. This is why cold chain integrity from manufacturer to your refrigerator matters more than most users realize.
The third omission is the glucagon receptor component and its metabolic consequences. GCGR agonism raises blood glucose transiently in fasting states. Users who skip meals and inject retatrutide may experience more pronounced glucose fluctuations than they would with semaglutide or tirzepatide. This is not discussed on most user-facing pages.
Retatrutide vs. Semaglutide vs. Tirzepatide: Honest Comparison
| Feature | Retatrutide | Tirzepatide | Semaglutide (injectable) |
|---|---|---|---|
| Receptor targets | GLP-1R, GIPR, GCGR (triple) | GLP-1R, GIPR (dual) | GLP-1R (single) |
| Administration | Once weekly SC injection | Once weekly SC injection (FDA-approved pen) | Once weekly SC injection (FDA-approved pen) |
| Regulatory status (US, mid-2026) | Investigational only, not approved | Approved (Mounjaro, Zepbound) | Approved (Ozempic, Wegovy) |
| Highest reported mean weight loss (best trial arm) | ~24.2% at 48 weeks (Phase 2) | ~22.5% at 72 weeks (SURMOUNT-1, Phase 3) | ~15% at 68 weeks (STEP 1, Phase 3) |
| Evidence quality | Phase 2 only (1 trial) | Multiple Phase 3 RCTs, FDA-reviewed | Multiple Phase 3 RCTs, FDA-reviewed, CVOT data |
| Long-term safety data | Very limited (48 weeks, 1 trial) | Moderate (Phase 3 trials, 72 weeks, ongoing CVOT) | Strong (SUSTAIN, STEP, LEADER CVOT) |
| Product form for end user | Lyophilized powder, requires reconstitution | Pre-filled pen, ready to inject | Pre-filled pen, ready to inject |
| Where retatrutide loses | No approval, no cGMP guarantee, no CVOT, no long-term safety data, manual reconstitution error risk | Loses on evidence depth vs semaglutide; wins on weight loss magnitude | Loses on weight loss magnitude vs both above |
How to Read a Retatrutide COA and Label
A legitimate Certificate of Analysis for a research peptide should include: the peptide sequence or CAS number, HPLC purity (look for a chromatogram, not just a number), mass confirmation by mass spectrometry, batch or lot number, manufacture date, and the name of the testing laboratory. If the COA is on the same company letterhead as the supplier, that is a conflict of interest. Third-party laboratory testing is the minimum credibility threshold.
On the product label itself, verify: net content in milligrams (not just a volume), recommended storage temperature, and lot number matching the COA. If these three items are not all present and matching, do not use the product.
HPLC purity of 98% or above is the commonly cited minimum for research-grade peptides. Values below 95% should be rejected. But again: HPLC purity does not equal pharmaceutical-grade safety. Endotoxin testing (LAL test, limulus amebocyte lysate) is the additional test that distinguishes a more credible supplier. Ask for it. Most suppliers do not perform it.
What Side Effects Should You Expect and When?
In the Jastreboff 2023 Phase 2 trial, GI adverse events were the dominant side effect class. Nausea, vomiting, diarrhea, and constipation occurred most frequently during dose escalation phases and were described as predominantly mild to moderate. Discontinuation due to adverse events was higher in the 8 mg and 12 mg groups than in lower dose groups or placebo, though the trial was not powered to give precise comparative discontinuation rates.
Practical management: eat smaller portions, avoid high-fat or high-sugar meals on injection day, stay hydrated, and do not escalate dose if GI symptoms have not stabilized at the current dose. If vomiting prevents adequate hydration for more than 24 hours, contact a clinician.
The GCGR component adds a theoretical risk of transient hyperglycemia in fasting states not present with semaglutide or tirzepatide. Individuals with diabetes using insulin or sulfonylureas face hypoglycemia risk from the GLP-1 component and should have those medications adjusted by a prescribing clinician before starting.
FAQ
How do you take retatrutide peptide?
Retatrutide is administered as a once-weekly subcutaneous injection, typically into the abdomen, thigh, or upper arm. The dose is started low (usually 0.5 mg or 1 mg per week) and escalated gradually over months to reduce GI side effects.
What needle size is used for retatrutide injections?
A 29 to 32 gauge, 4 to 8 mm pen or insulin syringe needle is appropriate for subcutaneous injection. Shorter 4 mm needles reduce the risk of inadvertent intramuscular injection, especially in leaner individuals.
What is the typical dose escalation schedule for retatrutide?
The Phase 2 trial (Eli Lilly, NEJM 2023) used escalation steps from 0.5 mg up to a maximum of 12 mg weekly over roughly 24 weeks. Most protocols hold each dose step for 4 weeks before advancing, depending on tolerability.
How do you reconstitute retatrutide from lyophilized powder?
Add bacteriostatic water slowly along the vial wall, not directly onto the powder. Gently swirl, never shake. Allow the solution to sit for 1 to 2 minutes until fully clear. Calculate your volume per dose based on the total mass reconstituted divided by your target concentration.
Where on the body should retatrutide be injected?
Rotate between the abdomen (at least 2 inches from the navel), outer thigh, and upper arm. Rotation prevents lipohypertrophy, which can reduce and unpredictably alter absorption. Never inject into the same spot consecutively.
How should retatrutide be stored?
Unreconstituted lyophilized retatrutide should be refrigerated at 2 to 8 degrees Celsius and kept away from light. Once reconstituted with bacteriostatic water, most research peptide guidance suggests use within 28 days under refrigeration, though formal stability data for non-pharmaceutical grade material is limited.
Can you take retatrutide with food?
Retatrutide is injected, not oral, so food timing does not affect absorption. However, GIP and GLP-1 receptor agonism slows gastric emptying considerably. Eating smaller, lower-fat meals around injection day can reduce nausea during dose escalation.
What happens if you miss a retatrutide dose?
If fewer than 4 days have passed since the scheduled dose, inject as soon as possible and resume the normal weekly schedule. If more than 4 days have passed, skip the missed dose and resume on the next scheduled day. Do not double-dose.
How is retatrutide different from semaglutide in terms of how you take it?
Both are once-weekly subcutaneous injections. Semaglutide (Ozempic, Wegovy) is FDA-approved with pharmaceutical-grade pre-filled pens. Retatrutide is not yet approved and is only available as a research compound or via compounding, requiring manual reconstitution and dose calculation.
What are the most common side effects when taking retatrutide?
In the NEJM Phase 2 trial (2023), nausea, vomiting, diarrhea, and constipation were the most frequent adverse events, occurring predominantly during dose escalation. Most were mild to moderate and transient. Serious GI adverse events were uncommon but occurred more often at higher dose groups.
Is retatrutide legal to use?
Retatrutide is not FDA-approved. In the US it exists as an investigational compound. Purchase and self-administration outside a clinical trial occupies a legal grey area. It is not approved for human use and is not the same as a compounded drug prescribed by a licensed clinician.
How long does it take for retatrutide to work?
In the Phase 2 trial, meaningful weight loss separation from placebo appeared by week 4 to 8. Maximum weight loss effect in that trial was measured at 48 weeks, with the highest dose group (12 mg) achieving approximately 24.2% mean body weight reduction.
Sources
- Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial. New England Journal of Medicine. 2023;389(6):514-526.
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine. 2022;387(3):205-216.
- Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine. 2021;384(11):989-1002.
- Drucker DJ. GLP-1 physiology informs the pharmacotherapy of obesity. Molecular Metabolism. 2022;57:101351.
- Nauck MA, Meier JJ. GIP and GLP-1: stepsiblings rather than twins. Diabetes. 2019;68(5):897-900.
- US Food and Drug Administration. Tirzepatide (Mounjaro) Prescribing Information. Revised 2023. Available at: fda.gov.
- US Food and Drug Administration. Semaglutide (Wegovy) Prescribing Information. Revised 2023. Available at: fda.gov.
- Spollett GR. Insulin injection technique: recommendations for optimizing outcomes. Diabetes Spectrum. 2012;25(4):265-269. (For lipohypertrophy and rotation evidence)